Jade Biosciences, Inc.: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management, L.P. amended its Schedule 13G filing for Jade Biosciences, Inc., updating its beneficial ownership stake with the SEC under accession number 0001346824-26-000283. The amendment signals a change in the size of the healthcare-focused investor's position in the biotech company. Schedule 13G filings are required of investors holding more than 5% of a class of registered equity securities, making the revision a marker of RA Capital's continued large stake. Investors will watch for the specific share count and percentage disclosed in the amended filing to gauge whether the firm added to or trimmed its holding.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Jade Biosciences, Inc., RA Capital Management, L.P.